Assessment of the immunogenicity and safety of varying doses of an MF59 ®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects

Vaccine

Volumn 30, Issue 33, 2012, Pages 5030-5037

  Fukase, Hiroyuki ^a   Furuie, Hidetoshi ^b   Yasuda, Yuji ^c   Komatsu, Ryoya ^d   Matsushita, Kenji ^e   Minami, Taketsugu ^f   Suehiro, Yutaka ^g   Yotsuyanagi, Hiroshi ^h   Kusadokoro, Haruko ⁱ   Sawata, Hiroshi ⁱ   Nakura, Noriko ⁱ   Lattanzi, Maria ^j  

^a CPC Clinic   (Japan)

^b Osaka Pharmacology Clinical Research Hospital   (Japan)

^c Yasuda Clinic   (Japan)

^d Ryoya Komatsu Clinic   (Japan)

^e Kamoike Seikyou Clinic   (Japan)

^f Minami Clinic   (Japan)

^g SAISEIKAI NAKATSU HOSPITAL   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ Novartis Pharma   (Japan)

^j NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

more..

Author keywords

Adjuvant; Cell culture; Influenza vaccine; MF59; Pandemic H1N1

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MIFAMURTIDE;

2009 H1N1 INFLUENZA; ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CELL CULTURE; CHILD; CHILL; CONTROLLED STUDY; CRYING; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; EATING HABIT; ECCHYMOSIS; ERYTHEMA; FATIGUE; FEMALE; FEVER; GERIATRIC PATIENT; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; IRRITABILITY; JAPANESE; MALAISE; MALE; MYALGIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SHIVERING; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; SWEATING; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; CHILD; CHILD, PRESCHOOL; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; JAPAN; MALE; MIDDLE AGED; POLYSORBATES; SQUALENE; TECHNOLOGY, PHARMACEUTICAL; VACCINATION; YOUNG ADULT;

EID: 84862753466     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.053     Document Type: Article

References (43)

1. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292(September (11)):1333-1340.
2. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289(January (2)):179-186.
3. Ferguson N.M., Cummings D.A., Fraser C., Cajka J.C., Cooley P.C., Burke D.S. Strategies for mitigating an influenza pandemic. Nature 2006, 442(July (7101)):448-452.
4. World Health Organization Production and availability of pandemic (H1N1) 2009 vaccines 2009, http://www.who.int/csr/disease/swineflu/frequently_asked_questions/vaccine_preparedness/production_availability/en/index.html.
5. O'Hagan D.T., Wack A., Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?. Clin Pharmacol Ther 2007, 82(December (6)):740-744.
6. Schultze V., D'Agosto V., Wack A., Novicki D., Zorn J., Hennig R. Safety of MF59 adjuvant. Vaccine 2008, 26(June (26)):3209-3222.
7. Banzhoff A., Pellegrini M., Del Giudice G., Fragapane E., Groth N., Podda A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respir Viruses 2008, 2(November (6)):243-249.
8. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370(August (9587)):580-589.
9. Stephenson I., Nicholson K.G., Hoschler K., Zambon M.C., Hancock K., DeVos J., et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008, 359(October (15)):1631-1633.
10. Erlewyn-Lajeunesse M., Brathwaite N., Lucas J.S., Warner J.O. Recommendations for the administration of influenza vaccine in children allergic to egg. BMJ 2009, 339:b3680.
11. Reisinger K.S., Block S.L., Izu A., Groth N., Holmes S.J. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis 2009, 200(September (6)):849-857.
12. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008, 197(March (5)):667-675.
13. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354(March (130):1343-1351.
14. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(December (25)):2424-2435.
15. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361(December (25)):2405-2413.
16. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375(January (9708)):56-66.
17. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoche M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375(January (9708)):41-48.
18. Vajo Z., Tamas F., Sinka L., Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010, 375(January (9708)):49-55.
19. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361(December (25)):2414-2423.
20. Arguedas A., Soley C., Lindert K. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N Engl J Med 2010, 362(January (4)):370-372.
21. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010, 303(January (1)):37-46.
22. Deaths related to 2009 pandemic influenza A (H1N1) among American Indian/Alaska Natives-12 states. MMWR Morb Mortal Wkly Rep 2009, 58(December (48)):341-344.
23. Kamigaki T., Oshitani H. Epidemiological characteristics and low case fatality rate of pandemic (H1N1) 2009 in Japan. PLoS Curr 2009, 1:RRN1139.
24. Yasuda Y., Komatsu R., Matsushita K., Minami T., Suehiro Y., Sawata H., et al. Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children. Adv Ther 2010, 27(July (7)):444-457.
25. World Health Organization. Global alert and response. Characteristics of the emergent influenza A (H1N1) viruses and recommendations for vaccine development. http://www.who.int/csr/resources/publications/swineflu/vaccine_recommendations/en/index.html.
26. European Medicines Agency EU recommendation for the emergent novel H1N1 influenza vaccine composition 2009, Committee for Human Medicinal Products, London, http://www.emea.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500015392.pdf.
27. World Health Organization. Global alert and response. Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development X-179A. http://www.who.int/csr/resources/publications/swineflu/candidates_X-179a/en/index.html.
28. Szymczakiewicz-Multanowska A., Groth N., Bugarini R., Lattanzi M., Casula D., Hilbert A., et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis 2009, 200(September (6)):841-848.
29. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37(April (4)):937-943.
30. Center for Biological Evaluation and Research Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines 2007, Food and Drug Administration, Silver Spring, MD, May.
31. CHMP. Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core. Dossier Context EMEA/CPMP/VWP/263499/2006; 24 January 2007.
32. CHMP. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (revision, EMEA/CPMP/VEG/4717/2002-Rev1); 18 December 2008.
33. Waddington C.S., Walker W.T., Oeser C., Reiner A., John T., Wilkins S., et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010, 340:c2649.
34. Arguedas A., Soley C., Abdelnour A., Sales V., Lindert K., Della Cioppa G., et al. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Hum Vaccin 2011, 7(January (1)):58-66.
35. Vesikari T., Groth N., Karvonen A., Borkowski A., Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009, 27(October (45)):6291-6295.
36. Vesikari T., Knuf M., Wutzler P., Karvonen A., Kieninger-Baum D., Schmitt H.J., et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011, 365(October (15)):1406-1416.
37. Vesikari T., Pellegrini M., Karvonen A., Groth N., Borkowski A., O'Hagan D.T., et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009, 28(July (7)):563-571.
38. Banzhoff A., Haertel S., Praus M. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Hum Vaccin 2011, 7(May (5)):539-548.
39. Frey S., Vesikari T., Szymczakiewicz-Multanowska A., Lattanzi M., Izu A., Groth N., et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010, 51(November (9)):997-1004.
40. Podda A., Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003, 2(April (2)):197-203.
41. Banzhoff A., Gasparini R., Laghi-Pasini F., Staniscia T., Durando P., Montomoli E., et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009, 4(2):e4384.
42. Pellegrini M., Nicolay U., Lindert K., Groth N., Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009, 27(November (49)):6959-6965.
43. Onions D., Egan W., Jarrett R., Novicki D., Gregersen J.P. Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals 2010, 38(September (5)):544-551.